MERTK INHIBITOR-ASSOCIATED RETINAL TOXICITY IN A HUMAN
Authors:
- Anne Strong CaldwellACAnne Strong Caldwell
- Dallin C. MilnerDMDallin C. Milner
- Nihaal B. MehtaNMNihaal B. Mehta
- Alejandro I. MarinAMAlejandro I. Marin
- Zafar S. GillZGZafar S. Gill
- Niranjan ManoharanNMNiranjan Manoharan
- 1 November 2025
- journal article
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 19 (6) , 807-810
Abstract
Background/Purpose: The MER proto-oncogene tyrosine kinase (MERTK) helps maintain the homeostasis of the retinal pigmented epithelium. In addition, MERTK regulates the innate immune system. As such, inhibition of MERTK has gained recent interest as a target for cancer therapeutics. Herein, we present MERTK inhibitor-associated retinal toxicity in a human. Methods: A 43-year-old man with medical history of esophageal adenocarcinoma was enrolled in a trial studying the MERTK inhibitor PF-07265807. As part of the study protocol, the patient was seen every 2 to 3 weeks for dilated fundus examinations and ancillary testing. Data on the patient's relevant medical history, ophthalmic examination findings, and imaging performed at baseline and subsequent ophthalmology visits were obtained through retrospective chart review. Results: At the patient's baseline visit, his dilated examination and testing were normal. Seven months after starting the MERTK inhibitor, the patient developed subtle but reproducible signs of retinal toxicity with disruption of the extrafoveal ellipsoid zone on optical coherence tomography and extrafoveal hyperautofluorescence on short wavelength fundus autofluorescence. The patient's vision remained stable throughout the study; however, the medication was stopped because of the unknown ocular effects and progression of the patient's cancer. Conclusion: Patients taking MERTK inhibitors should be monitored by an ophthalmologist while on the drug. If toxicity develops, discussion of whether to continue the medication should take place between the patient, ophthalmologist, and oncologist, with consideration of the risks of vision loss versus benefits of taking the medication from a cancer perspective.Keywords
This publication has 17 references indexed in Scilit:
- Pharmacological inhibition of MERTK induces in vivo retinal degeneration: a multimodal imaging ocular safety assessmentArchives of Toxicology, 2022
- MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune systemPharmacology & Therapeutics, 2020
- MERTK mutation update in inherited retinal diseasesHuman Mutation, 2018
- Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trialHuman Genetics, 2016
- The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancerNature Reviews Cancer, 2014
- Clinical characterisation of a family with retinal dystrophy caused by mutation in the Mertk geneBritish Journal of Ophthalmology, 2006
- AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosaMolecular Therapy, 2003
- Retinal Dystrophy Due to Paternal Isodisomy for Chromosome 1 or Chromosome 2, with Homoallelism for Mutations in RPE65 or MERTK, RespectivelyThe American Journal of Human Genetics, 2002
- Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosaNature Genetics, 2000
- Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS ratHuman Molecular Genetics, 2000